Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring stage II colon cancer, stage III colon cancer, stage II gastric cancer, stage III gastric cancer, recurrent gastric cancer, stage II rectal cancer, stage III rectal cancer, recurrent colon cancer, stage III ovarian epithelial cancer, recurrent ovarian epithelial cancer, regional gastrointestinal carcinoid tumor, small intestine adenocarcinoma, small intestine lymphoma, small intestine leiomyosarcoma, recurrent small intestine cancer, peritoneal cavity cancer, gastrointestinal stromal tumor
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage III ovarian epithelial cancer or gastrointestinal cancer with peritoneal involvement Patients with ovarian cancer must have completed first induction treatment with a platinum based regimen (carboplatin and/or cisplatin) and be in clinical complete response at time of assessment for study No ovarian cancer of low malignant potential PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Greater than 2 months Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin less than 1.5 mg/dL SGOT less than 3 times upper limit of normal Renal: Creatinine clearance at least 40 mL/min Other: No underlying medical or psychiatric condition that precludes informed consent PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Laparoscopy or laparotomy required within 8 weeks of study to assess residual disease
Sites / Locations
- NYU School of Medicine's Kaplan Comprehensive Cancer Center